Single Dose IV Tranexamic Acid is Safe for use in Hip Arthroscopy.

The primary purpose of this study was to determine if TXA is safe to administer preoperatively for patients undergoing hip arthroscopy by comparing the rate of VTE and complications between patients who did and did not receive TXA pre-operatively. This is a multicenter consecutive cohort series of patients that underwent arthroscopic hip surgery from 2014-2021. The two cohorts were patients who did and did not receive TXA preoperatively (single dose of 1-2g) after a practice change. Data was collected via chart review. Surgical outcomes included: days until follow up, Visual Analog Scale (VAS) pain scores at first follow-up, total operating room time, number of arthroscopic fluid bags (3 liters/bag), complications and revision operations up to 1 year after surgery. A Mann-Whitney U test was performed for continuous variables and chi square test for categorical variables. A total of 862 patients were identified: 449 (52%) did receive TXA and 413 (48%) did not. Patient demographics including age, sex, height, weight, BMI, smoking status, procedures performed, number of anchors used (no TXA: 3.5 anchors; TXA 3.7 anchors), and traction time (no TXA: 38 minutes; TXA: 40 minutes) did not significantly differ between groups. Significantly more patients had a prior hip arthroscopy in the group that received TXA (primary n=404; prior hip arthroscopy n=45) compared to the group that did not receive TXA (primary n=388; prior hip arthroscopy n=25) (p=0.03). VAS pain scores at the first follow up visit (no TXA: 2.61; TXA: 2.62 TXA) (p=0.62) and need for subsequent revision surgery were not significantly different (n=24 no TXA and n=18 TXA) (p=0.68). TXA use was associated with less arthroscopic fluid utilization (no TXA: 5.9 bags of 3L fluid; TXA: 5.3 bags of 3L fluid) (p<0.01) and less total operating room (OR) time (no TXA: 99.5 minutes; TXA: 90.0 minutes) (p<0.01). There was a higher overall complication rate in the no TXA group (n=27) compared to the TXA group (n=10) (p=0.01). However, if lateral femoral cutaneous nerve neuropraxia was excluded, then no difference in complication rate was observed (p=0.24). There was no difference in the incidence of VTE complications between patients that did and did not receive TXA preoperatively. We observed a lower overall complication rate in patients who received TXA preoperatively; however, this normalized between the two groups when LFCN neuritis was excluded. No difference in early pain control or revision surgery rates were observed between groups. While there was statistically less arthroscopic fluid utilization and less total OR time in the group that received TXA, further studies are needed to clarify whether this is clinically meaningful. In conclusion, preoperative administration of TXA is a safe adjunct medication for patients undergoing arthroscopic hip surgery.

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.